Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-25-321142

Chief Scientific Officer sold 8,500 shares at an average $30.02 ($255,130)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Bredt David Chief Scientific Officer 2025-12-15 Sale 10b5-1 −7,704 $29.95 $230,711 393,438 D
Bredt David Chief Scientific Officer 2025-12-15 Sale 10b5-1 −796 $30.68 $24,419 392,642 D
Open-market sales · 8,500 sh · avg $30.02 · $255,130
Loading xslF345X05/ownership.xml…